

GESTION DES VOIES AÉRIENNES EN RÉANIMATION

SESSION 1

**La ventilation invasive chez les patients SDRA COVID:
spécificités et problématiques**

Pf G. CARTEAUX — APHP H. Mondor



AP-HP.
Hôpitaux universitaires
Henri-Mondor



MOOC
EIVASION



UNIVERSITÉ
PARIS-EST
CRETEIL
VAL DE MARNE


UPEC

La ventilation invasive chez les patients SDRA COVID: spécificités et problématiques

Guillaume Carteaux

Médecine Intensive Réanimation, CHU Henri Mondor, Créteil

guillaume.carteaux@aphp.fr



hm ir
mondor

www.reamondor.aphp.fr

Conflicts of interest


- Fees and/or travel expanses
 - Medtronic
 - Fisher and Paykel
 - Air Liquide Medical System
 - Löwenstein
 - Dräger

SDRA et ventilation protectrice




Syndrome de Détresse Respiratoire Aiguë

« Baby lung »



Syndrome de Détresse Respiratoire Aiguë


Humidification des gaz inspirés



3e génération bronchique:


37°C


44 mg H₂O/l (humidité relative
= 100%)





?










Branche expiratoire





Branche expiratoire



« Baby lung »



Syndrome de Détresse Respiratoire Aiguë




Low compliance in ARDS: small lung not stiff lung

Luciano Gattinoni

Gattinoni L, Pesenti A. *Intensive Care Med* 2005: The concept of « baby lung »

VILI

Ventilator induced lung injury




Prévention du VILI

Réduction de la surdistension

- *Réduire du volume courant*
- *Limiter la pression télé-inspiratoire*
 - *Limiter le niveau de PEP*

Réduction des lésions à bas volume

- Recrutement alvéolaire:
 - *Augmenter le niveau de PEP*
 - Décubitus ventral




Lung Recruitment in Patients with the Acute Respiratory Distress Syndrome


Luciano Gattinoni, M.D., F.R.C.P., Pietro Caironi, M.D., Massimo Cressoni, M.D., Davide Chiumello, M.D., V. Marco Ranieri, M.D., Michael Quintel, M.D., Ph.D., Sebastiano Russo, M.D., Nicolò Patroniti, M.D., Rodrigo Cornejo, M.D., and Guillermo Bugedo, M.D.

2006

B Lower Percentage of Potentially Recruitable Lung



C Higher Percentage of Potentially Recruitable Lung



SDRA COVID: concernant la mécanique respiratoire et la recrutabilité, que diriez-vous?

- Tous les patients ont globalement les mêmes caractéristiques
- Il existe 2 phénotypes: le phénotype L et le phénotype H
- Il existe une grande variabilité inter-individuelle


COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Luciano Gattinoni^{1*}, Davide Chiumello², Pietro Caironi^{3,4}, Mattia Busana¹, Federica Romitti¹, Luca Brazzi⁵
and Luigi Camporota⁶


Intensive Care Med (2020) 46:1099–1102



$\text{PaO}_2/\text{FiO}_2$
95 mmHg



$\text{PaO}_2/\text{FiO}_2$
84 mmHg



COVID-19 pneumonia, Type L


At the beginning, COVID-19 pneumonia presents with the following characteristics:

- **Low elastance.** The nearly normal compliance indicates that the amount of gas in the lung is nearly normal [4].
- **Low ventilation-to-perfusion (VA/Q) ratio.** Since the gas volume is nearly normal, hypoxemia may be best explained by the loss of regulation of perfusion and by loss of hypoxic vasoconstriction. Accordingly, at this stage, the pulmonary artery pressure should be near normal.
- **Low lung weight.** Only ground-glass densities are present on CT scan, primarily located subpleurally and along the lung fissures. Consequently, lung weight is only moderately increased.
- **Low lung recruitability.** The amount of non-aerated tissue is very low; consequently, the recruitability is low [5].

COVID-19 pneumonia, Type H

The Type H patient:

- **High elastance.** The decrease in gas volume due to increased edema accounts for the increased lung elastance.
- **High right-to-left shunt.** This is due to the fraction of cardiac output perfusing the non-aerated tissue which develops in the dependent lung regions due to the increased edema and superimposed pressure.
- **High lung weight.** Quantitative analysis of the CT scan shows a remarkable increase in lung weight (> 1.5 kg), on the order of magnitude of severe ARDS [12].
- **High lung recruitability.** The increased amount of non-aerated tissue is associated, as in severe ARDS, with increased recruitability [5].



COVID-19 pneumonia: different respiratory treatments for different phenotypes?



Luciano Gattinoni^{1*}, Davide Chiumello², Pietro Caironi^{3,4}, Mattia Busana¹, Federica Romitti¹, Luca Brazzi⁵
and Luigi Camporota⁶

Intensive Care Med (2020) 46:1099–1102



Luciano Gattinoni

“Based on detailed observation of several cases and discussions with colleagues treating these patients, we hypothesize that the different COVID-19 patterns found at presentation in the emergency department...”



Luciano Gattinoni

“At this stage, dyspnea develops, which in turn leads to worsening P-SILI”

“As esophageal pressure swings increase (...) to above 15 cmH₂O, the risk of lung injury increases and therefore intubation should be performed as soon as possible”


L Gattinoni *et al.* *Intensive Care Med* 2020



Martin J Tobin


“At this time, the existence of P-SILI is based only on the shakiest of circumstantial evidence and has yet to be exposed to the acid-wash of experimental testing by differing scientists.”

M J Tobin *et al.* *Ann Intensive Care* 2020






<https://www.youtube.com/watch?v=6GijfVyflw>




Officer Chauvin's Orientation

Officer Chauvin's is near vertical. His toes are off the ground, signifying half his body weight (91.5 lbs.) is directly compressing the neck; with his toes on the ground, the weight on the neck is 86.9 lbs. (half the shank's weight is supported by the toes).




10 patients SDRA COVID, examen post-mortem



Macroscopic (A and B) and histologic (C) images of organizing and end-stage diffuse alveolar damage (hematoxylin-eosin staining) with hyaline membranes (D, arrowheads, $\times 100$), multinucleated giant cells (E, arrowheads, $\times 400$),

and squamous/osseous metaplasia (F and G, arrowheads, $\times 200$) in a patient with a fatal course of coronavirus disease 2019.




7 COVID vs. 7 H1N1 vs. 10 poumons normaux








COVID et H1N1: DAD mais poids poumons H1N1 > COVID

COVID: 9 x plus de microthrombi

COVID: distorsion, tortuosité du lit vasculaire; phénomènes angiogéniques







A

B


C

D









E






N = 32 CARDs



30 COVID-19 ARDS vs. 30 Non-COVID-19 ARDS, matching: P/F – FiO₂ - PEEP



Study	Type of Study N	PaO ₂ /FiO ₂ inclusion criteria	Respiratory System Compliance	Baseline values	
				Plateau Pressure	Driving Pressure
LUNG SAFE Bellani et al, JAMA 2016; 315:788	Observational 2377	<=300	32	23.2	-
OLA Kacmarek et al, Crit Care Med 2016; 44:32	RCT 200	<=200	28.5	25.8	14.1
ART Cavalcanti et al, JAMA 2017; 318:1335	RCT 1010	<=200	29.7	26	13.5
PETAL Moss et al, New Engl J Med 2019; 380:1997	RCT 1006	<=200	-	25.6	12.9
PRONE Guerin et al, New Engl J Med 2013; 368:2159	RCT 466	<=150	35.5	23.5	-
AVERAGE			32.1	24.8	13.1
Our study Ferrando et al.	Observational 742	< =300	35.2 (32.0-35.8)	25.0 (24.0-26.0)	13.1 (12.0-13.4)
Comparison with the AVERAGE value (p-value)			0.062	0.404	0.808




LUNG SAFE

N = 1 117 ARDS NON COVID

H Phenotype (CRS < 40): 74 %

L Phenotype (CRS \geq 50): 12 %


Intermediate Phenotype
 $(40 \leq \text{CRS} < 50)$: 14 %






Volume courant ≈ 6 ml/kg de PPT


$\Delta P < 15 \text{ cm H}_2\text{O}$

Pression de plateau $\leq 30 \text{ cm H}_2\text{O}$












R/I






www.sdrapps.fr

<https://crec.coemv.ca/>

R/I




R/I





www.sdrapps.fr

<https://crec.coemv.ca/>

Faible potentiel
de recrutement






ORIGINAL

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study




Julie Helms^{1,2}, Charles Tacquard³, François Severac⁴, Ian Leonard-Lorant⁵, Mickaël Ohana⁵, Xavier Delabranche³, Hamid Merdji^{1,6}, Raphaël Clère-Jehl^{1,2}, Malika Schenck⁷, Florence Fagot Gendet⁷, Samira Fafi-Kremer^{2,8}, Vincent Castelain⁷, Francis Schneider⁷, Lélia Grunebaum⁹, Eduardo Anglés-Cano¹⁰, Laurent Sattler⁹, Paul-Michel Mertes³, Ferhat Meziani^{1,6*} and CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis)



	Population before matching (<i>n</i> =383)				Population after matching (<i>n</i> =222)			
	Non-COVID-19-ARDS (<i>n</i> =233)	COVID-19-ARDS (<i>n</i> =150)	OR [95% IC]	p-value	Non-COVID-19-ARDS (<i>n</i> =145)	COVID-19-ARDS (<i>n</i> =77)	OR [95% IC]	p-value
Thrombo-embolic complications— <i>n</i> (%)	14 (6)	27 (18)	3.4 [1.7–7.3]	<0.001	7 (4.8)	9 (11.7)	2.6 [1.1–6.1]	0.04
Pulmonary embolisms— <i>n</i> (%)	3 (1.3)	25 (16.7)	15.2 [4.5–80.4]	<0.001	3 (2.1)	9 (11.7)	6.2 [1.6–23.4]	0.01

CPA




NC-ARDS: $\approx 22\%$

Mekontso Dessap A et al. *Intensive Care Med* 2016

C-ARDS: $\approx 38\%$

Cavaleiro P et al. *Crit Care* 2021

FOP




Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome*


Armand Mekontso Dessap, MD, PhD; Florence Boissier, MD; Rusel Leon, MD; Serge Carreira, MD; Ferran Roche Campo, MD; François Lemaire, MD; Laurent Brochard, MD

Crit Care Med 2010 Vol. 38,


First 48 hours after intubation



Outcomes at Day 14



SDRA COVID : P/F 95 mm Hg, compliance = 30 ml / cm H₂O,
PEP = 10 cm H₂O



COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Eddy Fan, Jeremy R Beitler, Laurent Brochard, Carolyn S Calfee, Niall D Ferguson, Arthur S Slutsky, Daniel Brodie

treatment in ARDS. In this Viewpoint, we address ventilatory strategies in the context of recent discussions on phenotypic heterogeneity in patients with COVID-19-associated ARDS. Although early reports suggested that COVID-19-associated ARDS has distinctive features that set it apart from historical ARDS, emerging evidence indicates that the respiratory system mechanics of patients with ARDS, with or without COVID-19, are broadly similar. In the absence of evidence to support a shift away from the current paradigm of ventilatory management, we strongly recommend adherence to evidence-based management, informed by bedside physiology, as resources permit.

En conclusion: Personnalisation de la VAC du SDRA COVID

- Principes de ventilation protectrice

- $V_t \approx 6 \text{ ml/kg PPT}$
- $P_{plat} \leq 30 \text{ cm H}_2\text{O}$
- $\Delta P < 15 \text{ cm H}_2\text{O}$
- Personnalisation de la PEP
- Décubitus ventral

⇒ **Raisonnement multi-paramétrique**

⇒ **Evaluation des interventions**

- Phénotypage du patient

- P/F $PaCO_2$
- Mécanique respiratoire, P_{plat} , ΔP
- R/I, AOP
- Caractéristiques extra-respiratoires